FY2025 EPS Estimate for X4 Pharmaceuticals Lifted by Analyst

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Research analysts at Brookline Capital Management raised their FY2025 earnings per share estimates for X4 Pharmaceuticals in a note issued to investors on Wednesday, November 5th. Brookline Capital Management analyst L. Cann now expects that the company will earn ($3.10) per share for the year, up from their previous estimate of ($4.30). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. Brookline Capital Management also issued estimates for X4 Pharmaceuticals’ Q4 2025 earnings at ($0.56) EPS, FY2026 earnings at ($1.50) EPS, FY2027 earnings at ($1.70) EPS and FY2028 earnings at ($0.42) EPS.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its earnings results on Wednesday, November 5th. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.10. X4 Pharmaceuticals had a negative return on equity of 343.67% and a negative net margin of 279.86%.The company had revenue of $1.77 million for the quarter, compared to analyst estimates of $2.05 million.

XFOR has been the topic of several other reports. Stifel Nicolaus set a $7.50 price objective on X4 Pharmaceuticals in a research report on Wednesday, November 5th. HC Wainwright set a $3.50 target price on shares of X4 Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of X4 Pharmaceuticals in a report on Wednesday, October 8th. Finally, Zacks Research raised shares of X4 Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.67.

X4 Pharmaceuticals Trading Down 2.8%

Shares of X4 Pharmaceuticals stock opened at $3.53 on Monday. X4 Pharmaceuticals has a 1 year low of $1.35 and a 1 year high of $26.83. The company has a debt-to-equity ratio of 1.23, a current ratio of 5.65 and a quick ratio of 5.48. The business has a 50 day moving average price of $3.40 and a 200 day moving average price of $2.98. The company has a market capitalization of $40.28 million, a P/E ratio of -0.35 and a beta of 0.51.

Insider Buying and Selling at X4 Pharmaceuticals

In related news, Chairman Adam R. Craig purchased 86,206 shares of the firm’s stock in a transaction on Thursday, October 23rd. The shares were bought at an average price of $2.90 per share, for a total transaction of $249,997.40. Following the acquisition, the chairman directly owned 376,087 shares in the company, valued at $1,090,652.30. This trade represents a 29.74% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. 2.15% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in XFOR. Bank of America Corp DE grew its position in shares of X4 Pharmaceuticals by 20.3% in the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after acquiring an additional 22,485 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in X4 Pharmaceuticals by 9.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company’s stock worth $114,000 after purchasing an additional 43,320 shares during the last quarter. Pale Fire Capital SE boosted its holdings in X4 Pharmaceuticals by 45.2% in the first quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company’s stock worth $481,000 after purchasing an additional 633,398 shares during the period. Kingdon Capital Management L.L.C. boosted its holdings in X4 Pharmaceuticals by 41.8% in the first quarter. Kingdon Capital Management L.L.C. now owns 7,000,000 shares of the company’s stock worth $1,655,000 after purchasing an additional 2,063,000 shares during the period. Finally, Rhumbline Advisers increased its stake in X4 Pharmaceuticals by 5.4% during the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares during the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.